Precision CMO Alan List (Diane Bondareff/AP Images for Moffitt Cancer Center)

ASH: An­oth­er 'off-the-shelf' cell ther­a­py leader shows dura­bil­i­ty is­sues, rais­ing re­newed con­cerns about emerg­ing field

The next gen­er­a­tion of cell ther­a­pies have fo­cused in large part on the de­vel­op­ment of al­lo­gene­ic — bet­ter known as “off-the-shelf — drugs that can cut man­u­fac­tur­ing times and hope­ful­ly evade a pa­tient’s im­mune sys­tem. One of the ear­ly play­ers in that race has new da­ta at #ASH21 that show deep re­spons­es but will al­so raise fresh con­cerns about these ther­a­pies’ dura­bil­i­ty.

Pre­ci­sion Bio­sciences’ PB­CAR0191, a CD19-di­rect­ed al­lo­gene­ic CAR-T cell ther­a­py, post­ed a com­plete re­sponse rate of 59% in 22 heav­i­ly pre­treat­ed pa­tients with var­i­ous forms of re­lapsed or re­frac­to­ry non-Hodgkin’s lym­phoma and acute lym­pho­cyt­ic leukemia, six of whom had pre­vi­ous­ly re­ceived an au­tol­o­gous CAR-T be­fore dos­ing, the biotech said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.